Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales revenue was ¥8 million, primarily from sales revenue from episil products, etc. Product sales remain at an early stage, and upfront investments in pharmaceutical development and other expenses exceeded profit from product sales. Research and development expenses were ¥230 million, while selling, general and administrative expenses increased ¥21 million year on year to ¥347 million.
Not applicable (no matters to report in the notes on the going concern assumption)
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥8 million (YoY -82.5%) |
| Operating profit | ¥-570 million |
| Ordinary income | ¥-579 million |
| Profit attributable to owners of the parent | ¥-579 million |
| Net income per share | △¥2.14 |
| Equity ratio | End of the current fiscal period 76.6 / End of previous period 81.7 |
| Total assets | ¥1,897 million |
| Net assets | ¥1,452 million |
| Cash flows from operating activities | ¥-325 million |
| Cash flows from investing activities | ¥-34 million |
| Cash flows from financing activities | ¥242 million |
| Cash and cash equivalents at end of period | ¥1,289 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks Full-year consolidated earnings forecasts for the fiscal year ending December 2026 are not provided because it is difficult to calculate reasonable earnings forecasts. |
| Revision to Earnings Forecast | None (estimates of product sales revenue, expenses, etc.) |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥18 million |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 273,414,365 |
| Treasury Shares at Period-End | 409,143 |
| Factors Behind Changes in Business Performance | Sales revenue was ¥8 million, primarily from sales revenue from episil products, etc. Product sales remain at an early stage, and upfront investments in pharmaceutical development and other expenses exceeded profit from product sales. Research and development expenses were ¥230 million, while selling, general and administrative expenses increased ¥21 million year on year to ¥347 million. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Product sales remain at an early stage, and the company continues to make upfront investments in pharmaceutical development that exceed profit from product sales. The company explained that it has already received payment for Sancuso, but recognition of sales revenue is expected to be delayed until the third quarter because the required documentation procedures associated with the change in sales partners have not yet been completed.